Company
IMEL Biotherapeutics
Mitochondrial Enhancement for T Cell Reprogramming
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- IMEL Biotherapeutics
Claim, correct or request removal
Record updated 28 September 2026
About
IMEL is developing a novel game-changing mitochondrial replacement approach for cell-based therapies. Its core technology demonstrates a remarkable >90% replacement of dysfunctional mitochondria.
Funding snapshot
- Total raised
- $15MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $15M2021-10-29
Funding rounds
- Round, 2021
- $15M2021-10-29, SEC form D sold, 5 investors
Products
- Other
- Autologous mitochondria-replaced T cells (Mir T Cells)
Loading relationship preview